NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Capital World Investors

Capital World Investors boosted its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 17.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,822,711 shares of the company’s stock after acquiring an additional 1,434,986 shares during the period. Capital World Investors owned 8.72% of NewAmsterdam Pharma worth $279,358,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Jennison Associates LLC lifted its position in shares of NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after purchasing an additional 1,252,451 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after acquiring an additional 1,062,359 shares during the period. Maverick Capital Ltd. boosted its stake in NewAmsterdam Pharma by 178.8% in the second quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock valued at $27,742,000 after acquiring an additional 982,405 shares during the period. Frazier Life Sciences Management L.P. grew its holdings in shares of NewAmsterdam Pharma by 3.0% during the second quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after purchasing an additional 490,656 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of NewAmsterdam Pharma by 47.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,458,897 shares of the company’s stock worth $26,421,000 after purchasing an additional 467,579 shares during the period. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $31.35 on Thursday. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $42.00. The stock has a market capitalization of $3.60 billion, a PE ratio of -18.12 and a beta of 0.04. The firm has a 50 day simple moving average of $33.34 and a 200-day simple moving average of $33.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.92 million. On average, analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Michael H. Davidson sold 443,707 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the completion of the sale, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at $5,790,288. This represents a 71.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $30.30, for a total value of $3,165,350.10. Following the completion of the transaction, the insider owned 69,302 shares of the company’s stock, valued at $2,099,850.60. This trade represents a 60.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 1,422,314 shares of company stock worth $47,090,707. 20.84% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NAMS. Wall Street Zen downgraded NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. The Goldman Sachs Group increased their target price on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 2nd. HC Wainwright upgraded NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. Stifel Nicolaus boosted their price target on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $47.10.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.